Pancreatic Cancer Clinical Trials

116 studies are recruiting for pancreatic cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

   The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal can…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber/Massachusetts General Hospital, Inc, Boston, Massachusetts

   Locations

   9 in total

   Run by

   PAQ Therapeutics, Inc.

   See if you can join NCT07300150 on ClinicalTrials.gov

2. EXoPERT EMERALD Clinical Study

   The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicl…

   Stage

   Not phased

   Ages

   45 and older

   Site

   Tibor Rubin VA Medical Center, Long Beach, California

   Locations

   9 in total

   Run by

   EXoPERT

   See if you can join NCT07186296 on ClinicalTrials.gov

3. Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

   This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.

   Stage

   Phase 1

   Ages

   40 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT05013216 on ClinicalTrials.gov

4. Integrated Cancer Repository for Cancer Research

   The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

   Stage

   Not phased

   Ages

   19 to 110

   Site

   Advent Health, Greenwood Village, Colorado

   Locations

   42 in total

   Run by

   University of Nebraska

   See if you can join NCT02012699 on ClinicalTrials.gov

5. A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

   The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation. In addition, the researchers are doing this study to find …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07671339 on ClinicalTrials.gov

6. Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

   This is a phase I study of an agonistic CD40 antibody (mitazalimab) injected intratumorally at the time of surgical IRE in patients with locally advanced pancreatic cancer. Intratumoral delivery has potential to be more effective than systemic (intravenous) delivery while decreasing the systemic si…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSD Moores Cancer Center, La Jolla, California

   Run by

   University of California, San Diego

   See if you can join NCT06205849 on ClinicalTrials.gov

7. A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

   RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California

   Locations

   3 in total

   Run by

   RasCal Therapeutics, Inc.

   See if you can join NCT04678648 on ClinicalTrials.gov

8. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center /ID# 276272, Duarte, California

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT05005403 on ClinicalTrials.gov

9. Familial Investigations of Childhood Cancer Predisposition

   NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor …

   Stage

   Not phased

   Ages

   Any age

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT03050268 on ClinicalTrials.gov

10. Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

    The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with metastatic or unresectable …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Virginia, Charlottesville, Virginia

    Run by

    University of Virginia

    See if you can join NCT06479239 on ClinicalTrials.gov

11. Lidocaine Infusion in Pancreatic Cancer

    This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will …

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    University of Illnois at Chicago, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT04048278 on ClinicalTrials.gov

12. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

    This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    2 in total

    Run by

    Memgen, Inc.

    See if you can join NCT05076760 on ClinicalTrials.gov

13. Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

    The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06122896 on ClinicalTrials.gov

14. Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

    This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Mississippi Medical Center, Jackson, Mississippi

    Locations

    2 in total

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT05687188 on ClinicalTrials.gov

15. High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

    Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies. These advances have resulted in a myriad of benefits for patients including decreased morbidit…

    Stage

    Not phased

    Ages

    19 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05053555 on ClinicalTrials.gov

16. Video Education With Result Dependent dIsclosure

    The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better s…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT05225428 on ClinicalTrials.gov

17. BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

    BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX c…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cross Cancer Institue, Edmonton, Alberta

    Locations

    24 in total

    Run by

    Bold Therapeutics, Inc.

    See if you can join NCT04421820 on ClinicalTrials.gov

18. Brodalumab in the Treatment of Immune-Related Adverse Events

    The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University Irving Medical Center, New York, New York

    Run by

    Brian Henick, MD

    See if you can join NCT06673329 on ClinicalTrials.gov

19. Pancreatic Cancer Genetics

    The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary …

    Stage

    Not phased

    Ages

    18 to 85

    Site

    Columbia University Medical Center, New York, New York

    Run by

    Columbia University

    See if you can join NCT01102569 on ClinicalTrials.gov

20. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Denver, Colorado

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

21. NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

    The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06941857 on ClinicalTrials.gov

22. PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

    This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their dise…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT07549958 on ClinicalTrials.gov

23. A 2-part Phase 1/2 Open-label Trial on ODM-212

    An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, Irving, Texas

    Locations

    2 in total

    Run by

    Orion Corporation, Orion Pharma

    See if you can join NCT07563738 on ClinicalTrials.gov

24. Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

    Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone mar…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT02838836 on ClinicalTrials.gov

25. MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06648434 on ClinicalTrials.gov